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Objective: Treatment of relapses in multiple sclerosis (MS) has not advanced beyond steroid use, which reduces acute
loss of function, but has little effect on residual disability. Acute loss of function in an MS model (experimental autoim-
mune encephalomyelitis [EAE]) is partly due to central nervous system (CNS) hypoxia, and function can promptly
improve upon breathing oxygen. Here, we investigate the cause of the hypoxia and whether it is due to a deficit in
oxygen supply arising from impaired vascular perfusion. We also explore whether the CNS-selective vasodilating agent,
nimodipine, may provide a therapy to restore function, and protect from demyelination in 2 MS models.
Methods: A variety of methods have been used to measure basic cardiovascular physiology, spinal oxygenation, mito-
chondrial function, and tissue perfusion in EAE.
Results: We report that the tissue hypoxia in EAE is associated with a profound hypoperfusion of the inflamed spinal
cord. Treatment with nimodipine restores spinal oxygenation and can rapidly improve function. Nimodipine therapy
also reduces demyelination in both EAE and a model of the early MS lesion.
Interpretation: Loss of function in EAE, and demyelination in EAE, and the model of the early MS lesion, seem to be
due, at least in part, to tissue hypoxia due to local spinal hypoperfusion. Therapy to improve blood flow not only pro-
tects neurological function but also reduces demyelination. We conclude that nimodipine could be repurposed to offer
substantial clinical benefit in MS.
ANN NEUROL 2020;00:1–14
Modern therapies for multiple sclerosis (MS) have sig-nificantly reduced the frequency of relapses in
treated patients.1 However, when relapses occur there is
little evidence that they are any less severe than before
therapy, and their treatment has barely advanced over the
6 decades since steroids were first used. Steroids seem to
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provide little or no long-term benefit in treating acute
optic neuritis, a disease related to MS, and, although ste-
roid administration can curtail the severity and duration of
relapses in MS, any small improvement in long-term out-
come2 has to be weighed against the adverse side effects of
steroid use. The absence of an effective therapy is a concern
because relapses can result in permanent and severe loss of
function, and a third of patients treated with steroids fail to
make a full recovery.3 This therapeutic need is further
highlighted by the recent finding that the number of early
relapses is associated with an increased risk of developing
progressive disease and can, therefore, be used to identify
those who may benefit from more active acute therapy.4
We have previously reported that loss of neurological
function at the onset of experimental autoimmune encepha-
lomyelitis (EAE) is due to spinal hypoxia,5,6 in conjunction
with loss of mitochondrial function,7,8 and these challenges
correlate with the expression of neurological deficit. Here,
we aim to identify the mechanisms responsible for the hyp-
oxia in a common laboratory model of MS (EAE), and,
armed with this knowledge, to develop a rational therapy to
protect neurological function in acute relapse.
We additionally hypothesized that overcoming hyp-
oxia could confer protection against the demyelination
that characterizes both EAE and MS. Reducing demyelin-
ation is important because it avoids the associated axonal
conduction block and production of symptoms.9 It also
avoids leaving axons vulnerable to degeneration and per-
manent loss of function. One type of demyelination, com-
mon in the early forming MS lesion, is of the pattern III
subtype10 now shown to be due to focal tissue
hypoxia,11,12 and, in this study, we determine whether
therapy designed to prevent hypoxia is effective in reduc-
ing demyelination not only in EAE but also the pattern
III demyelination in a model of the early MS lesion.
Our multidisciplinary approach has been to examine
2 neuroinflammatory demyelinating models of MS in rats,
namely a commonly used model of EAE5 and a model of
pattern III demyelination mediated by intraspinal injec-
tion of lipopolysaccharide (LPS).12 We hypothesized that
reversing spinal hypoxia in these models using
nimodipine, a central nervous system (CNS)-specific vaso-
dilator, would offer dual benefits of reducing disability
and preventing permanent structural damage.
Methods
Animal Models
Experiments were performed in accordance with the UK
Animals (Scientific Procedures) Act of 1986, and the
ARRIVE guidelines.
Recombinant Myelin Oligodendrocyte Glycoprotein
EAE. EAE was induced in adult female Dark Agouti rats
(DA), as previously described,5 and animals “immunized”
with incomplete Freund’s adjuvant (IFA)5 served as con-
trols in all experiments. Briefly, animals received a subcu-
taneous injection of either an emulsion consisting of
100 μg recombinant myelin oligodendrocyte glycoprotein
(rMOG) in IFA, or an emulsion consisting of equivalent
volumes of IFA and saline, at the dorsal aspect of the base
of the tail (200 μL) while they are under anesthesia (1.5%
isoflurane in room air).
Experimental Pattern III Demyelinating Lesion. The experi-
mental pattern III demyelinating lesion was induced in
adult male Sprague Dawley rats. A quarter laminectomy
was performed between the T13 and L1 vertebrae while
the rats were under deep isoflurane anesthesia (2% in oxy-
gen) and LPS (0.5 μL of 100 ng/μL in saline; Salmonella
enterica abortus equi; Sigma-Aldrich, Dorset, UK) micro-
injected into the right dorsal column at depths of 0.7 and
0.4 mm, followed by an intramuscular injection of
Vetergesic. The wound was closed with sutures and sterile
wound clips and the animals were monitored daily for any
adverse reactions, as previously described.12
Basic Cardiovascular Physiology
Animals with EAE (n = 9) and time-matched IFA controls
(n = 7), were anaesthetized (5% isoflurane in room air for
induction and 1.5% for maintenance) at the first peak of
disease expression for detailed assessment. A rectal temper-
ature probe connected to a homeothermic heating mat
enabled maintenance of normothermia (Harvard Appara-
tus, Cambridge, UK). Transthoracic echocardiography, to
determine myocardial function, was performed using a
14 MHz probe scanning at 0 to 2 cm depth (Vivid
7 Dimension; GE Healthcare, Bedford, UK). Aortic blood
flow velocities were determined in the aortic arch using
pulsed-wave Doppler. After the echocardiogram, the left
common carotid artery and right internal jugular vein
were cannulated using 0.96 mm outside diameter PVC
tubing catheter (Biocorp Ltd, Huntingdale, New South
Wales, Australia). The arterial line was connected to a
pressure transducer (Powerlab; AD Instruments,
Chalgrove, UK) for continuous monitoring of mean arte-
rial pressure. The venous line was used for subsequent
administration of fluids (0.9% NaCl, 10 mL/kg/h). A tra-
cheostomy was achieved using 2.08 mm external diameter
polythene tubing (Portex Ltd, Hythe, Kent, UK) to secure
and enable suction of the airway. Whole blood (100 μL)
was collected from the carotid arterial line into heparinized
capillary tubes (Brand GMBH, Wertheim, Germany) for
blood-gas analysis (ABL 90 FLEX, Radiometer, Crawley,
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UK), including measurement of the partial pressures of oxy-
gen (PaO2) and carbon dioxide (PaCO2), pH, hemoglobin
(quantity, percentage oxygen bound, and calculated p50),
glucose, lactate, and electrolytes (K+, Na+, Ca2+, and Cl−).
At the end of the experiment, animals were euthanized by
terminal anesthesia (5%).
Spinal Measurements in vivo in EAE
At the first peak of disease expression, a laminectomy was
performed at the T13/L1 vertebral junction (2% iso-
flurane in room air), and the spinous process of L1
removed to expose the dorsal aspect of the lumbar enlarge-
ment, in EAE and IFA time-matched control animals, as
previously described.5 A rectal temperature probe con-
nected to a homeothermic heating mat (Harvard Appara-
tus, Cambridge, UK) enabled maintenance of
normothermia throughout the experiment and global arte-
rial oxygen saturation was monitored continuously by
pulse oximetry (MouseOx; STARR Life Sciences,
Oakmont, PA) via a hind foot sensor. Anesthesia was
maintained (1.5% isoflurane in room air) for the duration
of the experiment. Where appropriate, photomicrographs
were taken of the exposed spinal surface (Nikon D1000
camera).
Spinal Oxygen Measurements. An oxygen probe (NX-BF/
O/E; 250 μm tip diameter; OxyLite Pro; Oxford
Optronix, Oxon, UK) was inserted into the spinal grey
matter of EAE (n = 9) and IFA control (n = 7) animals
(measurements were taken from the spinal grey matter as
the oxygen concentration in the spinal white matter can
be too low to detect accurately with the probe), through a
small opening in the dura for measurement of spinal tissue
oxygen tension (tPO2) under light anesthesia (1.5% iso-
flurane in room air). The fraction of inspired oxygen
(FiO2) was then increased from 21% to 100% for an
additional 10-minute period. At the conclusion of the
experiment, animals were euthanized by terminal anesthe-
sia (5% isoflurane in room air).
Assessment of Spinal Tissue Pressure/Edema. A measure of
spinal/cerebral spinal fluid (CSF) pressure was obtained
using calibrated von Frey hairs to determine the force
required to depress the dura, in animals with EAE
(n = 20) versus time-matched IFA controls (n = 6).
Broadband Near-Infrared Spectroscopy in vivo in EAE
Animals. Needle fiber optic probes with a metal ferrule at
the end (500 μm diameter) were used as source and detec-
tor fibers and positioned on the exposed dorsal surface of
the spinal cord at the first peak of disease expression in
rats with EAE (n = 11) and time-matched IFA controls
(n = 9) while under light anesthesia (1.5–2% isoflurane)
using a micromanipulator. Care was taken to avoid the
dorsal vein in the midline, which could interfere with
measurements due to the large absorption. A
broadband-near-infrared spectroscopy (bNIRS) instru-
ment developed in-house was used to calculate changes
in the concentrations of deoxygenated (HHb), and oxy-
genated hemoglobin (HbO2), together with oxidized
cytochrome C oxidase (oxCCO), based on the mea-
sured changes in light attenuation through the spinal
cord (780–900 nm) using the UCLn algorithm every
10 seconds. The concentrations were expressed in μM.
cm as the spinal cord tissue differential pathlength fac-
tor was not known.
Magnetic Resonance Imaging in EAE Animals
Longitudinal in vivo magnetic resonance imaging (MRI)
measurements were performed on a 9.4 T Agilent scanner
(Agilent Technologies, Santa Clara, CA) using a volume
coil with an inner diameter of 72 mm (Rapid Biomedical
GmbH, Rimpar, Germany) for radio frequency
(RF) transmission and a 2-element array coil for the signal
reception (Rapid Biomedical). Based on fast localization
imaging, the animals were placed in supine position such
that both the heart and the volume of interest were
included in the volume coil. The surface coil was placed
at the lumbar level and a protocol was developed that
overcame the technical challenges inherent to MRI of the
spinal cord,13 including the synchronization of data acqui-
sition with breathing to reduce motion artifacts. Perfusion
maps with an in-plane spatial resolution of 190 × 190
um2 at the lumbar level were obtained using an optimized
pre-saturation-FAIR-Q2TIPS ASL preparation combined
with a reduced field of view readout sequence. The acqui-
sition parameters were: recovery time = 3.2 seconds, TI1/
TI2 = 1.55/1.65 seconds, TE/TR = 20/5,015 ms, and an
acquisition time of 25 minutes. Briefly, after baseline mag-
netic resonance (MR) measurements, female DA rats were
randomly allocated to one of two groups, EAE (n = 7) or
controls (n = 6). Longitudinal MR scans were performed
at different stages of the disease: first peak (12–17 days
postimmunization [dpi]), remission (16–19 dpi), and
relapse (19–23 dpi). Animals were scanned while under
anesthesia (3% isoflurane in room air for induction and
1.5–2% maintenance). During scanning, body tempera-
ture was maintained at 37C with a heating pad, while
heart rate, respiration rate, and arterial oxygen saturation
were continuously monitored (Small Animal Instruments,
Stony Brook, NY). At the conclusion of the experiment,
animals were euthanized by terminal anesthesia (5%
isoflurane).
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Therapy in EAE and the Experimental Pattern III
Demyelinating Lesion
The CNS-selective vasodilator, nimodipine, was used to
determine whether (1) spinal oxygen and blood velocity
could be increased in EAE, (2) loss of function could be
acutely and chronically decreased in EAE, and (3) the
extent of demyelination could be decreased or prevented
in EAE and in the experimental pattern III MS lesion.
Drug. Nimodipine (Sigma Aldrich, Darmstadt, Germany),
or vehicle (1:4; ethanol:polyethylene glycol [PEG]) was
administered by oral gavage (30 mg/kg), intravenously
(1 mg/kg), or subcutaneously using implanted osmotic
minipumps (30 mg/kg; Alzet, Cupertino, CA), depending
on the experiment.
Nimodipine and Spinal Oxygenation. At the peak of dis-
ease (unilateral or bilateral hindlimb paralysis), the left
femoral artery was cannulated (2% isoflurane) to allow
continuous arterial blood pressure monitoring (Spike2
Software, Cambridge, UK), prior to performing a
laminectomy. A small hole was made in the dura approxi-
mately 700 μm lateral to the midline in EAE (n = 17) and
time-matched IFA control animals (n = 10), and an
oxygen-sensitive probe (<50 um tip diameter, OxyMicro,
World Precision Instruments, Sarasota, FL) inserted into
the spinal grey matter (1.5% isoflurane), as previously
described.5 Oxygen, rectal and body temperatures, arterial
blood pressure, and global arterial oxygen saturation were
recorded continuously. Following an initial stabilization
period of 5 minutes, a bolus of nimodipine (1 mg/kg,
EAE: n = 9; IFA: n = 6) or vehicle (1:1:3, ethanol:
PEG400: saline; EAE: n = 8; IFA: n = 4) was injected
intravenously into the tail vein. Recordings were contin-
ued for up to 1 hour following the intravenous injection,
until the spinal oxygen concentration stabilized.
Nimodipine and Blood Velocity. Animals with EAE were
selected for imaging at the first peak of disease and exam-
ined in conjunction with time-matched IFA controls
(EAE: n = 17; IFA: n = 9). The spinal cord beneath the
L2 vertebra was exposed by laminectomy (2% isoflurane
in room air), and the vertebral column stabilized using
side clamps. Rectal temperature was maintained at
35.5  2C using a homeothermic underblanket. The
dura was left intact and protected with warmed mineral
oil. The cord was illuminated using an X-Cite lamp and
viewed using an FITC filter (Filter Set 10; Zeiss United
Kingdom, Cambridge, UK). A full resolution image was
obtained with a charge-coupled device camera set to
1,000 ms exposure time (QImaging, Surrey, Canada).
Fluorescent microspheres (1.9 μm; ThermoFisher
Scientific, Paisley, UK) were administered via cannulation
of the femoral vein and imaged at 10 Hz, binning pixels
at 4 × 4. A bolus of nimodipine (1 mg/kg, EAE: n = 10;
IFA: n = 5) or vehicle (1:1:3, ethanol:PEG400:saline,
EAE: n = 7; IFA: n = 4) was administered intravenously.
Spinal blood flow was monitored for 45 minutes following
the intravenous injection, with a full resolution image and a
10 Hz recording taken at 5, 15, 30, and 45 minutes post-
injection. Velocity at each time point was determined by
typically making >40 measurements of streak length (dis-
tance travelled by a microsphere in one frame) and 10 mea-
surements of vessel diameter per recording. Images were
acquired using MicroManager and analyzed in ImageJ.
Nimodipine and Acute Loss of Function in EAE. EAE ani-
mals with a range of deficits were randomly allocated to
receive nimodipine (30 mg/kg: n = 30) or vehicle (1:4,
ethanol:PEG400; n = 18) via oral gavage, based on their
10-point neurological score. The scoring system com-
prised of points assigned based on the deficit observed,
with one point assigned for tail-tip weakness, tail-base
weakness, tail paralysis, absence of toe spreading reflex,
abnormal gait, hind limb paresis (left and right), hind
limb paralysis (left and right), and moribund.
Rectal temperature was measured before and after
nimodipine administration to explore whether the improve-
ment in neurological function may be due to a Uhthoff
effect9 due to body cooling.
Continuous Nimodipine and Disease Course in EAE. At the
onset of neurological deficit, animals were randomly allo-
cated to receive either nimodipine (30 mg/kg; n = 13) or
vehicle (ethanol: PEG400; n = 13) via subcutaneously
implanted osmotic minipumps (Alzet, Cupertino, CA).
Animals were evaluated daily for their neurological deficit,
in a blinded manner, until termination 12 days post-onset
of neurological deficit. Animals were perfused
transcardially with rinse followed by paraformaldehyde
(PFA),5 and the spinal cord harvested for histological eval-
uation. The gastrocnemius muscle was also harvested and
weighed.
Nimodipine and Experimental Pattern III Demyelina-
tion. Pattern III demyelinating lesions were induced as
described above. Following surgery, animals received an
intraperitoneal (i.p.) injection of nimodipine (30 mg/kg;
n = 20) or vehicle (ethanol:PEG400; n = 19). Animals
were allowed to recover and were administered either
nimodipine or vehicle via oral gavage at 10, 24, 36, and
48 hours postinjection. Animals were monitored daily for
any adverse effects and terminated via transcardial
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perfusion 14 days postinjection. Spinal cords were
harvested and processed for histological evaluation.
Histology and Microscopy
Harvested spinal cords were post-fixed in 4% PFA for
24 hours, with subsequent cryoprotection in 30% sucrose
(Sigma, Welwyn Garden City, UK) in phosphate-buffered
saline (PBS). The relevant regions of the cords (EAE: lum-
bar enlargement; pattern III lesion: injection site marked
with charcoal) were processed for cryosectioning and sta-
ined with Luxol fast blue, periodic acid Schiff, and hema-
toxylin (LFB/PAS/H) to assess demyelination. Every tenth
section from 200 sections (2,400 μm lesion) of pattern
III lesioned tissue was stained and examined to identify
the lesion epicenter. Demyelination was then quantified
using a section taken at the lesion epicenter. Tissue was
viewed using an Axiophot light microscope (Carl Zeiss,
Oberkochen, Germany) and photographed with a Nikon
D300 camera (Nikon Instruments, Melville, NY).
Histological Quantification
Quantification of white matter demyelination in EAE was
achieved by counting the number of pixels above a set
threshold and expressed as the percentage area coverage of
the spinal white matter. Lesion size in LPS-injected ani-
mals, as determined by myelin loss in LFB-stained sec-
tions was manually circumscribed and expressed as a
percentage of dorsal column area at the lesion epicenter.
One section per animal was used for the quantification of
demyelination. All quantification was carried out in a
blinded manner.
Statistics
Data are presented as mean  standard error or median,
quartiles, and range. Group sizes are indicated in the text.
Parametric data (following Shapiro–Wilk testing for nor-
mality) were analyzed using repeated measures 1-way or
2-way analysis of variance (ANOVA) followed by
Bonferroni’s post hoc testing, or an unpaired t-test, as
indicated. The Bonferroni correction was applied to adjust
the critical level for significance where multiple compari-
sons were conducted in order to control the family-wise
error rate. Nonparametric data were analyzed using the
Mann–Whitney U test, or Spearman’s correlation, as indi-
cated. All statistical analyses were 2-tailed and performed
using Prism 7.0.1 software (GraphPad Software, la Jolla,
CA). Multiplicity adjusted p values <0.05 were considered
statistically significant.
Results
Spinal Inflammation is Associated with Tissue
Hypoxia
Two independent measurements indicated hypoxia in the
spinal cord of animals with EAE. Direct measurement of
tissue oxygen tension (tPO2) in the spinal cord grey mat-
ter using a fiber-optic oxygen-sensitive probe (Oxford
Optronix, Abingdon, UK) in anesthetized rats showed
that those with EAE had significantly lower tissue oxygen
tensions (tPO2 = 29.01  2.78 mmHg; n = 9) than in
controls “immunized” with IFA (45.94  2.47 mmHg;
n = 7; unpaired t-test with Bonferroni correction for mul-
tiple comparisons: p < 0.005; Fig 1A).
Spinal/CSF Pressure is Associated
with Neurological Deficit
Photographs of the exposed lumbar spinal cord revealed
that the venous blood in animals with EAE appeared more
deoxygenated than the venous blood in time-matched
control IFA animals (Fig 1B). The spinal cord in the ani-
mals with EAE also appeared to be edematous, and this
correlated with the dorsal vein appearing wider, as if it
had been flattened beneath the pia. To gain a measure of
potential pressure changes in the lumbar cord we used cal-
ibrated von Frey hairs to determine the force needed to
depress the dura. The results revealed that the force
required was significantly larger in animals with EAE
(n = 20) than in IFA controls (n = 6) (Mann–Whitney
U test, U = 3.00, Z = −3.553; p < 0.001; Fig 1Bii). The
force required to depress the dura was also significantly
correlated with the severity of the neurological deficit
(Spearman’s correlation, r = 0.710; p < 0.001; 95% confi-
dence interval [CI] = 0.436–0.864).
FIGURE 1: Spinal oxygenation, edema, and global cardiorespiratory function. (A) Shows the spinal cord tissue PO2 measured by
a fiber-optic oxygen-sensitive probe. (B) The i and ii show representative images of the exposed spinal cord and graphical
representation of spinal edema in EAE and IFA controls. (C) Shows arterial PO2 obtained by blood gas analysis.
Echocardiography-derived cardiac output and carotid arterial mean blood pressure measurements are depicted in (D) and (E),
respectively. Echocardiography-derived fractional shortening, heart rate and stroke volume are shown in panels (F–H). Additional
determinants of oxygen delivery, glycemic status, and global indicators of organ perfusion are shown in (I, J, K, L, M, N, and O,
respectively). Data presented as mean  SEM. **p < 0.01, ***p < 0.001, unpaired t-test with Bonferroni correction (A: EAE:
n = 8; IFA: n = 7; C–H: EAE: n = 8; IFA: n = 6; I–O: EAE: n = 8; IFA: n = 7), Mann–Whitney U test (Bii: EAE: n = 20; IFA: n = 6).
CSF = cerebrospinal fluid; EAE = experimental autoimmune encephalomyelitis; IFA = incomplete Freund’s adjuvant; PO2 =
partial pressure of oxygen; PaCO2 = partial pressure of carbon dioxide; SaO2 = oxygen saturation; VFH = Von Frey Hairs.
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Hypoxia is CNS-Specific, Rather than Systemic
We next assessed global cardiorespiratory function to
examine whether the spinal hypoxia in EAE was due to a
systemic reduction in oxygen delivery. Global oxygen
delivery is a function of the quantity and saturation of
hemoglobin, and cardiac output. Arterial blood gas analy-
sis revealed no differences in the arterial partial pressure of
oxygen (arterial PO2; Fig 1C), blood hemoglobin levels,
or hemoglobin oxygen saturation between animals with or
without EAE. Cardiac output showed no difference
between treatment groups (Fig 1D), and, at the conclu-
sion of surgery (when the regional assessment of spinal
oxygenation took place), blood pressure was also similar in
both sets of animals (IFA controls: 137.6  3.33 mmHg,
EAE: 125.7  4.68 mmHg; Fig 1E). Although the
values for fractional shortening were slightly lower in ani-
mals with EAE compared with controls (IFA controls:
62.7  4.20%, EAE: 47.1  4.16%), the reduction was
not significant (Bonferroni correction, unpaired t-test:
t (12) = 2.57, p = 1.00; Fig 1F). Furthermore, echocardi-
ography revealed normal myocardial function, with heart
rate and stroke volume showing similar values between ani-
mals with or without EAE (Fig 1G,H). No deficits were
observed for blood sugar levels, the partial pressure of CO2,
or any other global indicators of organ hypoperfusion (such
as lactate levels or acid/base status; Fig 1F–O). These data
argue against a global cardiorespiratory abnormality in ani-
mals with EAE during the first peak of disease, and, thus,
the severe neurological deficits that occur in conjunction
with significant spinal hypoxia are likely to be driven by
mechanisms within the spinal cord.
Oxygen Administration Overcomes Spinal
Hypoxia and Improves Mitochondrial Function
Given that the inflamed spinal cord is hypoxic, we
sought to determine whether inspiratory hyperoxia could
overcome spinal hypoxia. Administration of high inspired
oxygen concentrations (70% O2) elevated tissue oxygen
tension beyond the normal range in animals with EAE,
as determined by an oxygen-sensitive probe (Oxford
Optronix, Abingdon, UK) inserted into the spinal grey
matter (Fig 2A).
We additionally used trans-spinal bNIRS to examine
not only the relative changes in spinal blood hemoglobin
oxygenation, but also the oxidation status of mitochon-
drial cytochrome-C-oxidase (a measure of mitochondrial
function) upon inspired normobaric hyperoxia (98.5%
O2). Expectedly, hyperoxia increased the mean spinal oxy-
genated hemoglobin in animals during the first peak of
neurological deficit due to EAE; the magnitude of this
increase was significantly higher in EAE (n = 11) versus
IFA (n = 9) controls (Fig 2B). Additionally, whereas
increasing inspired oxygen did not cause further oxidation
of cytochrome-C-oxidase in IFA controls, there was a sig-
nificant increase in the oxidation status of cytochrome-
C-oxidase in animals with EAE (Fig 2C). This finding
indicates an increase in mitochondrial oxygen utilization,
and, importantly, this result suggests that whereas spinal
mitochondria have a sufficient supply of oxygen in control
animals, their function is restricted by an inadequate oxy-
gen supply in EAE. Thus, the loss of neurological func-
tion during the first peak of neurological deficit in EAE
can be reasonably attributed, at least in part, to tissue hyp-
oxia and an energy crisis arising from mitochondrial defi-
cits. Alleviating this deficit by breathing oxygen improves
mitochondrial function, and this is associated with an
improvement in neurological function, as reported previ-
ously5 and confirmed in this study (results not shown).
Neurological Deficits and Spinal Hypoxia are
Associated with Spinal Hypoperfusion
We next explored whether the spinal hypoxia and neuro-
logical deficits are due to spinal hypoperfusion, and/or
driven by increased oxygen demand in the inflamed tissue.
We, therefore, made absolute quantitative measurements
of spinal cord blood flow (SCBF) in rats with EAE using
a novel MRI technique based on arterial spin labeling
(ASL). Animals were scanned at different stages of disease,
as reflected in the disease time course in Fig 3A; baseline/
pre-immunization (EAE n = 7, IFA control n = 6), peak
of first attack (EAE n = 7, IFA control n = 3), remission
(EAE n = 6, IFA control n = 3), and relapse (EAE n = 7,
IFA control n = 3).
FIGURE 2: Oxygen administration overcomes spinal hypoxia
and improves mitochondrial function. (A) Shows spinal cord
tissue PO2 measured by fiber-optic probe following
administration of high oxygen concentrations. The grey
shaded area shows the normal range obtained in IFA controls
breathing room air. (B and C) These panels respectively show
changes derived from trans-spinal broadband near-infrared
spectroscopy in oxyhemoglobin and oxidation of cytochrome
C oxidase. Data presented as mean  SEM. *p < 0.05, ****p
< 0.0001; unpaired t-test (A: EAE: n = 8; IFA: n = 7; B and C:
EAE: n = 11; IFA: n = 9). EAE = experimental autoimmune
encephalomyelitis; HbO2 = oxygenated hemoglobin; IFA =
incomplete Freund’s adjuvant; oxCCO = oxidation status of
cytochrome C oxidase; PO2 = partial pressure of oxygen.
[Color figure can be viewed at www.annalsofneurology.org]
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Average pre-immunization SCBF in grey and
white matter was 347  26 mL/100 g/min and
152  23 mL/100 g/min, respectively (Fig 3B,C). Sub-
sequently, SCBF in grey matter was significantly (2-way
ANOVA, F (3, 34) = 23.9, p < 0.0001; Fig 3B)
decreased in animals with EAE during both the first
peak of disease (# 31%, p < 0.001, 95% CI = −29.8 to
61.0) and relapse (# 47%, p < 0.001, 95%
CI = 242–135). Notably, blood flow recovered during
remission, and during an unusual improvement in func-
tion in one animal on day 23 postimmunization
(Fig 3A–D). Within the white matter, the only signifi-
cant change in SCBF was observed at relapse, where a
reduction in flow of 43% (2-way ANOVA, F (3, 34)
= 7.60, p < 0.001, 95% CI = −145 to 38.3) was
observed (Fig 3C. Thus, there was a strong association
between reduced spinal cord perfusion and loss of neu-
rological function. We conclude that the neurological
deficits at the first peak of neurological deficit in EAE
are due, at least in part, to spinal hypoxia arising from
hypoperfusion of the inflamed spinal cord.
Therapy with Nimodipine Improves Spinal Blood
Flow and Tissue Oxygenation
In view of the finding that reduced spinal cord blood flow
and reduced oxygenation accompany spinal hypoxia and loss
of neurological function, we next explored whether the L-type
calcium channel blocking agent nimodipine, which selectively
dilates CNS blood vessels and increases cerebral blood flow,14
is effective in restoring vascular perfusion, spinal oxygenation,
and neurological function in animals with EAE.
The impact of nimodipine on spinal blood flow veloc-
ity was measured by imaging fluorescent intravenous micro-
spheres in the dorsal spinal vein of anesthetized rats
(Supplementary Movie S1). Imaging was performed in the
L2 region in animals with EAE, and in time-matched con-
trols. Initial blood flow velocity was significantly (p < 0.0001)
reduced in animals at the first peak of disease expression in
FIGURE 3: Spinal cord blood flow. The disease time course of an EAE animal is shown in (A) with the following events indicated;
1, baseline (pre-immunization); 2, first peak of disease; 3, remission; 4, relapse; and 5, post-relapse improvement of symptoms.
The animal is unable to walk using its hind limbs at a neurological deficit >6. SCBF in the grey matter and white matter is shown
in (B) and (C), respectively. (D) Shows typical heat maps of SCBF for control and EAE rats at different time points during the
disease course. Although the disease course in A is representative of this EAE model up to day 22, an unusual and unexpected
improvement was observed on day 23 (indication point 5; improving). This improvement correlates with an increase in spinal
blood flow indicated in the MRI heat map in D. Data in B presented as mean  SEM. ***p < 0.001, ****p < 0.0001; 2-way
repeated measures ANOVA plus Bonferroni’s multiple comparison test (EAE: n = 7; IFA: n = 6). ANOVA = analysis of variance;
EAE = experimental autoimmune encephalomyelitis; MRI = magnetic resonance imaging; SCBF = spinal cord blood flow.
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EAE compared with IFA controls (Fig 4A,). Following intra-
venous nimodipine, blood flow velocity was significantly
(2-way ANOVA, F (3, 107) = 65.08, p < 0.0001, overall
ANOVA) enhanced in animals with EAE (n = 10), but had
no effect in controls (n = 5; Fig 4B). Vehicle administration
had no effect on spinal cord blood flow velocity in either
group (n = 7, EAE; n = 4, control; Fig 4B).
In separate studies, animals of equivalent disease sever-
ity (hindlimb paresis or paralysis) at the first peak of EAE
were anesthetized and an oxygen-sensitive probe (WPI)
inserted into the spinal grey matter at the T13 vertebra. In
line with the reduction in blood flow velocity, and our previ-
ous findings,5 tPO2 at the start of the experiment was signifi-
cantly reduced in EAE animals (n = 17; unpaired t-test,
t (24) = 5.46, p < 0.0001, 95% CI = 3.65–8.10) compared
with IFA controls (n = 9; Fig 4C). Intravenous administra-
tion of nimodipine, although inducing transient systemic
hypotension, was accompanied by a sustained (up to
30 minutes) significant increase in spinal tPO2 in animals
with EAE (n = 9; paired t-test, t (8) = −5.97, p < 0.001,
95% CI = −4.79 to −2.12; Fig 4D). Notably, the spinal
oxygen concentration in rats with EAE reached control spi-
nal oxygen levels, following nimodipine. No change in spinal
tPO2 was observed in IFA control animals given nimodipine
(n = 5; paired t-test, t (4) = −1.16, p = 0.311, 95% CI =
−3.40 to 1.40) or in either set of animals administered vehi-
cle (IFA control: n = 4; EAE, n = 8; Fig 4D).
Acute and Chronic Nimodipine Therapy Restores
Function
Given that a bolus of nimodipine reversed spinal hypoxia in
EAE, and that hypoxia in EAE is known to cause neurologi-
cal deficits,5 we next explored whether nimodipine is able to
restore neurological function in EAE. Animals with EAE on
the second or third day of disease expression were randomly
allocated to receive a single dose of either nimodipine
FIGURE 4: Effect of nimodipine on spinal cord blood flow and oxygenation. (A) Shows initial SCBF velocity in animals with EAE or
controls. (B) Shows changes in velocity normalized to each animal’s baseline velocity following treatment with either vehicle or
nimodipine. Velocities were measured in the dorsal spinal vein of anesthetized rats and revealed by fluorescent microspheres
suspended in the plasma and viewed through the intact dura. (C) Shows spinal tissue oxygenation in control animals compared
with animals with EAE. (D) Shows the change in spinal oxygenation in animals with EAE or controls prior to and following the
administration of nimodipine or vehicle. Nimodipine improves spinal oxygenation in animals with EAE from hypoxic to normoxic
levels. Data presented as mean  SEM. Stated p values reflect the outcome of an unpaired t-test in A and C (****p < 0.0001)
and following a 2-way repeated measures ANOVA in B and D. **p < 0.01; Bonferroni’s multiple comparison test (A, B: EAE +
drug n = 10, EAE + vehicle n = 7, IFA + drug n = 5, IFA + vehicle n = 4; C, D: EAE + drug n = 9, EAE + vehicle n = 8, IFA + drug
n = 6, IFA + vehicle n = 4). ANOVA = analysis of variance; EAE = experimental autoimmune encephalomyelitis; NIM =
nimodipine; SCBF = spinal cord blood flow; VEH = vehicle. [Color figure can be viewed at www.annalsofneurology.org]
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(n = 30; 30 mg/kg) or vehicle (n = 18) via oral gavage. We
found that nimodipine improved function in the majority of
animals. Moreover, the beneficial effects of a single oral dose
of nimodipine extended over several days, with nimodipine-
treated animals showing significantly less hind limb dysfunc-
tion than vehicle-treated animals (Fig 5A; 2-way ANOVA
with Bonferroni correction, F (4, 230) = 3.49, p = 0.009),
particularly at day 2 (p < 0.01; 95% CI = 0.197–2.08), day
3 (p < 0.001; 95% CI = 0.797–2.68) and day 4 (p < 0.001;
95% CI = 0.684–2.57). Importantly, animals treated with
nimodipine were able to walk 4 days following a single dose,
compared with animals that received vehicle, which were
unable to walk (Fig 5A): this is an especially important
improvement in clinical terms. We also found that the
treated rats showed a small increase in core body temperature
(+0.73C  0.17C), perhaps due to their increased physical
activity, and so the improvement in function could not be
due to body cooling.
To determine whether prolonged administration of
the drug would result in additional benefit, animals were
implanted with subcutaneous slow release mini-pumps
containing either nimodipine (loaded to release 30 mg/kg/
day for 7 days; n = 13) or vehicle (n = 13). Using the
10-point scale, we found that most (67%) animals given
nimodipine were able to walk throughout the first peak of
disease, whereas the majority of (77%) animals adminis-
tered vehicle exhibited a normal disease course, with hind
limb paralysis at a similar stage of disease (Fig 5B). In par-
ticular, animals treated with nimodipine showed a
significantly lower score for neurological deficit on days
3 (p < 0.05; 95% CI = 0.160–3.840) and 4 post-onset of
disease (p < 0.05; 95% CI = 0.160–3.840). The beneficial
effects of nimodipine persisted even after the pumps were
removed at 7 days, such that most (69%) drug-treated
animals retained some hind limb function, whereas most
(77%) vehicle-treated animals exhibited bilateral hindlimb
paralysis, and remained paralyzed at termination. Over the
entire disease course, treatment with nimodipine was able
to confer a significant (p < 0.0001) degree of protection
against loss of function. We additionally found that ani-
mals treated with nimodipine possessed significantly
(p < 0.05) more gastrocnemius muscle mass at termination
(nimodipine, 0.67  0.05 g vs vehicle, 0.54  0.03 g).
Chronic Therapy with Nimodipine Reduces
Demyelination in both EAE and a Model
of the Early MS Lesion
Histological examination of the lumbar spinal cord of ani-
mals with EAE at 28 days postimmunization revealed that
animals chronically (7-day mini pump) treated with
nimodipine exhibited significantly (Mann–Whitney U test,
U = 39.0, Z = −2.33; p < 0.021) less demyelination than
vehicle-treated controls (vehicle n = 13: 38.3  4.97%
cross-sectional area of the spinal white matter, nimodipine
n = 13: 20.2  4.06% cross-sectional area of the spinal
white matter; Fig 6A).
To determine whether nimodipine could reduce the
demyelination in a spinal model of the early MS pattern III
FIGURE 5: Restoration of function following acute and chronic nimodipine administration. (A) Shows the score for hindlimb
dysfunction (one point assigned for gait, toe spreading, hind limb paresis [left and right] and hind limb paralysis [left and right])
in the 4 days following a single administration of vehicle or drug. (B) Shows scores for neurological deficit in animals receiving
chronic nimodipine administration (subcutaneously via Alzet mini pumps) between 1 and 8 days after the onset of disease;
indicated by shading in the figure. Animals were assessed using a 10-point scale where a score of 6 signifies an inability to walk,
and 8 denotes hind limb paralysis. Data presented as mean  SEM. Stated p values reflect the outcome following a 2-way
repeated measures ANOVA in A and B. *p < 0.05, **p < 0.01, ***p < 0.001; Bonferroni’s multiple comparison test, A: EAE +
drug n = 20, EAE + vehicle n = 17; B: EAE + drug n = 13, and EAE + vehicle n = 13). ANOVA = analysis of variance; EAE =
experimental autoimmune encephalomyelitis. [Color figure can be viewed at www.annalsofneurology.org]
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lesion,12 rats were administered nimodipine (30 mg/kg;
i.p. immediately following surgery and p.o. subsequently;
n = 20) or vehicle (n = 19) for 2 days. Histological examina-
tion of the lesion epicenter 2 weeks after lesion induction rev-
ealed that nimodipine therapy significantly reduced the
magnitude of demyelination compared with controls (vehicle:
35.1%  3.93% cross-sectional area of dorsal column,
nimodipine: 15.8  4.71% cross-sectional area of dorsal
column; Fig 6B; Mann–Whitney U test, U = 77.0, Z =
−3.20, p = <0.0016). Notably, lesions failed to form in almost
half of the animals treated with nimodipine (n = 9) yet were
present in all controls treated with vehicle.
Discussion
The data collectively show that loss of neurological
function at the first peak of EAE is largely due to spinal
FIGURE 6: The effect of nimodipine on demyelination. Grouped data with representative micrographs are presented. (A) Shows
the percent demyelination across the entire spinal cord section in animals with EAE compared with controls, whereas graph
(B) shows the percentage demyelination of the dorsal columns in LPS-injected animals, following treatment with either vehicle or
nimodipine. Representative sections from control (top) and EAE animals (left), or LPS-injected animals (right), treated with
vehicle (middle) or nimodipine (bottom) labeled with LFB (left) or LFB/PAS/H (right) are shown in (C) where the paucity of
blue coloration in the white matter denotes demyelination. *p < 0.05, **p < 0.01; Mann–Whitney U test. Scale bars 0.5 mm.
EAE = experimental autoimmune encephalomyelitis; LFB/PAS/H = Luxol fast blue, periodic acid Schiff, and hematoxylin;
LPS = lipopolysaccharide; NIM = nimodipine; VEH = vehicle.
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hypoperfusion, hypoxia, and loss of mitochondrial func-
tion, which can result in a spinal energy crisis
preventing normal function and resulting in the expres-
sion of the observed neurological deficit. Therapy with
nimodipine, a CNS-selective vasodilator,14 not only
improves neurological function, but also protect against
demyelination in EAE, and against the pattern III type
of demyelination observed in early MS lesions, which
we have previously demonstrated to be due to focal tis-
sue hypoxia.12
To the best of our knowledge, this is the first
study examining perfusion within the spinal cord in rats
with EAE, and it has revealed that the expression of
neurological deficit is closely related to hypoperfusion
of the spinal cord, and that remission from functional
deficits is accompanied by improved perfusion. Hypo-
perfusion is well established in MS15,16 with delayed
arterial bolus arrival time,17 increased mean vascular
transit time,18 and long circulation time.19 It has been
uncertain whether the reduced perfusion is a physiologi-
cal response to reduced demand, or whether the
reduced perfusion may be causing functional and struc-
tural damage, but the evidence that the perfusion defi-
cits are associated with reduced cortical oxygenation20
indicates that the mismatch between perfusion (oxygen
delivery) and oxygen demand is, therefore, responsible
for causing damage. The perfusion deficits may expose
vulnerable niches in the brain to such severe hypoxia
that the local oligodendrocytes die, resulting in pattern
III demyelination.12,15 The evidence for hypoxia in MS
is in agreement with earlier results from microarray21
and immunohistochemical studies.11 It seems reason-
able that although hypoperfusion may represent the
main cause of the hypoxia in early EAE, when demye-
lination is absent, a significant increase in oxygen
demand by resident glial cells and infiltrating inflamma-
tory cells may also contribute to the tissue hypoxia, per-
haps exacerbated by demyelination at later stages of
disease.
A potential cause of spinal hypoperfusion is systemic
hypoperfusion, and, in MS, systemic cardiovascular dys-
function can occur as a result of autonomic disturbances,
physical incapacity, inflammation, and oxidative stress.22
We investigated whether systemic cardiorespiratory abnor-
malities could account for the observed regional hypoxia
but found that animals with EAE showed a broadly simi-
lar cardiovascular profile to their IFA-treated counterparts.
Thus, the severe neurological deficits, coupled with spinal
hypoxia, seem to result from pathological mechanism(s)
related to the spinal cord itself.
The current study supports previous findings that
the inflamed spinal cord can be severely hypoxic.5
Furthermore, we show that the hypoxia is associated with
mitochondrial failure as indicated by the ability of brief
hyperoxia to increase significantly the oxidation status of
mitochondrial cytochrome c oxidase in the spinal cord of
animals with EAE, but not in controls. Cytochrome C
oxidase is the terminal enzyme in the respiratory electron
transport chain that is responsible for reduction of oxygen
to water, and its activity can be limited when oxygen con-
centrations are low. Previous studies have shown that
under low oxygen concentrations, the activity of cyto-
chrome C oxidase becomes oxygen dependent23 well
above the commonly reported Km. Under inflammatory
conditions, such as in EAE, the consequences of hypoxia
are further exacerbated by copious amounts of nitric
oxide,5 and even nanomolar concentrations of this free
radical can increase the Km of cytochrome C for oxygen
and promote cell death. The current study shows that
mitochondrial failure is reversible, and that function can
be restored by increasing the concentration of inspired
oxygen.
We have found that the inflamed spinal cord is
hypoperfused, and it is reasonable to believe, first, that this is
an important cause of the hypoxia and impaired mitochon-
drial metabolism that accompany it, and, second, that these
phenomena contribute in turn to the loss of neurological
function, and to demyelination (see below). Belief in this
sequence of events is substantiated by our observations that
nimodipine, a CNS-specific vasodilator, not only promptly
improves flow, but also tissue oxygenation, neurological
function, and demyelination. The early recovery in function
indicates recovery from a metabolic compromise, but the
chronic improvement extending over days with sustained
administration of nimodipine may involve additional
mechanisms. For example, nimodipine has neuroprotective
properties and can, for example, protect cultured neurons
from glutamate-induced damage,24 and from oxygen and
glucose, and trophic, deprivation.25 Furthermore, nimodipine
protects dopaminergic neurons from axotomy-induced
death26 and from damage due to 1-methyl-
4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) poisoning.27
Nimodipine also has anti-inflammatory properties, including
significant inhibition of nitric oxide production, and of the
cytokines tumor necrosis factor-α and interleukin-1β.28,29
The beneficial effects of nimodipine have encouraged 2 recent
studies of the effects of nimodipine in murine EAE,30,31 and
treatment was found to result in a milder disease course with
reduced inflammation and demyelination, together with
repair by remyelination. The possibility of spinal hypo-
perfusion and its downstream consequences were not consid-
ered in the earlier studies, and so the beneficial effects of
nimodipine therapy on tissue hypoxia and neurological func-
tion were not considered.
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The observed protection from pattern III demyelin-
ation by nimodipine is consistent with our earlier observa-
tion that pattern III demyelination is due to hypoxia and
is reduced by breathing oxygen.12 However, the protec-
tion from demyelination observed in EAE is more surpris-
ing and it points to anti-inflammatory actions of
nimodipine (see above), perhaps in protecting or repairing
the integrity of the blood-brain barrier. The protection
may also indicate that some of the demyelination in EAE
is not directly mediated by autoimmunity, as often
believed, but may rather be due to the consequences of
hypoperfusion, including hypoxia and mitochondrial
failure.
The current findings encourage consideration that
nimodipine may be of value in the therapy of MS, given
that patients with MS exhibit hypoperfusion16 and CNS
hypoxia20 together with demyelination. Clinical use of
nimodipine is facilitated by the information that the drug
is already in human use to avoid complications following
subarachnoid hemorrhage,32 and the drug has already
been administered to 4 patients with MS to control parox-
ysmal symptoms.33
If used therapeutically in MS, we consider that
nimodipine may have particular benefit if administered
promptly at the onset of new relapses. The advantages
of hyperacute therapy have been stressed in optic neuri-
tis, a disease related to MS.34 We suggest that the start
of the neurological deficit signals the onset of focal
hypoperfusion and tissue hypoxia sufficient to cause
neuro/axonal inexcitability resulting in the loss of func-
tion. Although the neurons/axons are rendered inex-
citable, they remain viable so that conduction can be
restored by restoration of the vascular supply. Thus,
prompt administration of drugs like nimodipine can be
expected to reduce the severity, and curtail the dura-
tion, of a relapse. Beyond restoring function, the cur-
rent results show that therapy to improve blood flow
can also be expected to protect from demyelination,
thereby limiting the size of new lesions.
Nimodipine is also indicated as a therapy for MS
because the reduced cerebral perfusion in the disease
occurs in the presence of raised circulating concentrations
of the potent vasoconstrictive agent endothelin-1.35
Nimodipine can counteract the effects of endothelin-1, in
a similar way to bosentan, which has been demonstrated
to restore cerebral hypoperfusion in MS to within the con-
trol flow range.35
Aside from correcting hypoperfusion, it is possible to
improve oxygen delivery to the CNS by increasing the
hematocrit, and it is interesting in this context that ther-
apy with erythropoietin (EPO; which has a range of effects
but most notably boosts red cell production) improved
outcome in both a pilot study in progressive MS and a
phase II trial in optic neuritis.36,37
We conclude that strategies to improve perfusion
and oxygen delivery to the inflamed CNS may offer sub-
stantial clinical benefit in MS, and in other neurological
diseases where perfusion is reduced, including Alzheimer’s
disease and dementia.
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